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Fluticasone propionate pressurized metered dose inhalers (pMDIs) containing the hydrofluoroalkane (HFA) 
propellant, HFA 134a, are being developed to replace xisting chlorofluorocarbon (CFC) pMDls. This is part of 
the ongoing worldwide project o limit the damage to the earth's ozone layer. 
The h~ vivo performance and dose proportionality of fluticasone propionate HFA 134a pMDls was examined for 
fluticasone propionate doses of 400, 1000 and 2000/~g using the 50, 125 and 250 l~g strength pMDls, respectively. 
The 125 and 250 #g strength HFA 134a pMDls were compared with corresponding fluticasone propionate CFC 
pMDIs. Twenty-three healthy subjects participated in this single dose, randomized, five-way, cross-over study. 
Serial blood samples were collected 24 h post-dose to measure fluticasone propionate plasma concentrations. 
Twenty-four hour urinary-free cortisol was also measured before and after dosing. 
A dose-proportional increase in plasma fluticasone propionate concentrations was observed with increasing dose 
for the HFA 134a pMDIs. This was associated with a dose-related decrease in urinary cortisol excretion. Similar or 
lower fluticasone propionate systemic exposure was observed with the HFA 134a pMDIs compared to the 
corresponding CFC inhalers. The differences in systemic exposure observed for the HFA 134a and CFC pMDls 
were too small to produce a differential effect on urinary cortisol excretion. 
Since fluticasone propionate has negligible oral bioavailability, the systemic exposure, which arises only from 
pulmonary absorption, is a measure of lung deposition. There was a good correlation between the hi vitro fine 
particle mass produced by the different strengths and types of pMDI and the systemic exposure to fluticasone 
propionate. Therefore, the fluticasone propionate HFA 134a pMDI is an acceptable pharmaceutical alternative to 
the current CFC pMDI, producing similar lung deposition and no increase in systemic exposure at microgram 
equivalent doses. 
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Introduction 
Fluticasone propionate is a synthetic orticosteriod with 
potent anti-inflammatory activity in the lungs (1). Admin- 
istration of anti-inflammatory drugs via inhalation is the 
mainstay for the treatment of asthma nd other respiratory 
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diseases (2,3). Inhaled drug delivery maximizes, topical 
activity in the lungs and minimizes ide-effects (4). 
Pressurized metered ose inhalers (pMDIs) are the most 
widely used inhaled delivery system for the treatment of 
respiratory diseases (5,6) and until recently these contained 
chlorofluorocarbon (CFC) propellents. CFCs are being 
phased out worldwide due to their adverse ffects on the 
ozone layer. The originally marketed pMDIs for the 
delivery of fluticasone propionate used a combination of 
the propellants trichlorofluoromethane (PI I) and dichlor- 
odifluoromethane (PI2). Hydrofluoroalkane (HFA) 134a, 
1,1,1,2-tetrafluoroethane, has been developed as a CFC 
substitute, pMDIs that use HFA 134a as a propellant and 
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are pharmaceutically equivalent to the CFC products have 
been developed. This strategy allows a smooth transition to 
the replacement product without the need for dose 
adjustment and extensive re-eduction of patients and 
healthcare professionals. 
hi vitro pharmaceutical data have demonstrated that the 
fluticasone propionate HFA 134a pMDIs are fundamen- 
tally the same as the corresponding CFC pMDls with a 
similar particle size range and emitted fine particle mass 
(FPM) dose (7). Similar in vitro pharmaceutical character- 
istics have been associated with similar hi vitro performance 
for salbutamol HFA 134a and CFC pMDls (8-10). 
However, conflicting data have been presented on the 
clinical consequences of having pharmaceutically different 
profiles for beclomethasone dipropionate CFC and HFA 
134a pMDls (11-13). In this case, the hl vitro pharmaceu- 
tical differences between beclomethasone dipropionate 
CFC and HFA 134a pMDIs are translated into increases 
in systemic exposure for the HFA 134a pMDI. A similar in 
vitro pharmaceutical performance for the fluticasone propio- 
nate HFA 134a and CFC pMDI was therefore a prerequisite 
for a smooth transition between the two products. 
Fluticasone propionate has negligible oral bioavailabil- 
ity. due to extensive first pass metabolism by the liver 
(I.14): therefore, systemic exposure arises only from 
pulmonary absorption. As a result, the area under the 
fluticasone propionate plasma concentration-time curve 
(AUC) is an estimate of lung deposition. This provides a 
method of comparing lung deposition for the fluticasone 
propionate HFA 134a and CFC pMDIs. For drugs of this 
type, this approach is a good alternative to gamma 
scintigraphy, which requires preparation of specially made 
formulations, because pharmacokinetic and pharmacody- 
namic assessments can be made without altering the 
formulation. Furthermore, because this method accounts 
for issues such as mucociliary transport, it provides 
considerable information about the time-event profile of 
the drug in the body and gives a more accurate assessment 
of lung deposition. 
There is no direct link between systemic exposure and 
efficacy for inhaled corticosteroids; however, there is an 
established relationship between endogenous cortisol evels 
and systemic exposure to corticosteroids (15). Although, 
effects on hypothalamic pituitary adrenal axis function are 
only measurable after the administration of high-dose 
corticosteroid therapy to healthy subjects (16), such 
measures do provide an assessment of the relative potential 
for systemic effects. 
The objectives of this study were to investigate the h~ vivo 
performance and dose proportionality of drug delivery for 
the HFA 134a pMDls. This was assessed in terms of 
systemic exposure to fluticasone propionate and effects on 
urinary cortisol excretion. The relationship between emitted 
FPM dose and systemic exposure was examined for the 
three strengths for the fluticasone propionate HFA 134a 
inhaler (50, 125 and 250 #g) and for two strengths of the 
fluticasone propionate CFC inhaler (125 and 250 #g). A 
systemic pharmacokinetic and pharmacodynamic compar- 
ison was also conducted for the HFA 134a and CFC 
pMDIs for the 125 and 250 #g strengths. 
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Methods  
STUDY DESIGN 
This was a single centre, open-label, randomized, five-way 
cross-over study. The study was conducted at the Glaxo 
Wellcome Clinical Pharmacology Unit in Verona, Italy and 
the protocol was approved by an independent ethics 
committee. Written informed consent was obtained from 
each subject. 
At each of the five study sessions, healthy subjects were 
randomized to receive fluticasone propionate 400, 1000 or 
2000 #g, respectively, administered aseight oral inhalations 
from a 50, 125 and 250 #g HFA 134a pMDI, or fluticasone 
propionate 1000 or 2000 #g, respectively, administered as 
eight oral inhalations from a 125 and 250 #g CFC pMDI. 
The elapsed time from the first to the last (eighth) 
inhalation was 3.5 min. 
Subjects reported to the research facility two evenings 
before administration of the study drug. Each subject was 
instructed in the use of a pMDI and was asked to 
demonstrate proper inhaler technique using a placebo 
inhaler. Study drug was administered to each subject 
approximately 38h after admission to the facility, at 
approximately 09.00 hours. Safety evaluations were con- 
ducted for 24 h after drug administration, after which time 
the subjects were discharged. This was followed by a 5-day 
washout period and subjects then reported back to the 
research facility on the fifth evening at approximately 
19.00 hours. 
For 24 h before and during each study session, subjects 
were required to refrain from strenuous exercise and to 
avoid intake of alcohol and caffeinated beverages. In 
addition, subjects were not allowed to smoke during their 
stay in the unit, and were asked to avoid any concomitant 
medication for the duration of the study and to limit their 
fluid intake to approximately 1 l day- l .  
Blood samples (5 ml) were collected predose, at 10, 20, 
40, 60 and 90 min and at 2, 3, 4, 6, 8, 10, 12, 16, 20 and 24 h 
from the beginning of dosing for the determination of 
plasma fluticasone propionate concentrations. The samples 
were analysed for fluticasone propionate using solid-phase 
extraction in combination with liquid chromatography 
tandem mas~ spectrometry.oThe method required 0.5 ml 
of plasma nd was validated over the range 20-1520 ng l - I ;  
the limit of detection was 20 ng I - I .  
The following parameters were derived for each subject 
from the plasma fluticasone propionate data: 
• AUC from zero to the last quantifiable concentration 
(Cla~,) (AUCla~,) 
• AUC extrapolated to infinite time (AUC0-oo). This 
was calculated using the following equation: 
AUClast + Clast x tl/2/0"693 
• maximum plasma fluticasone propionate concentra- 
tion (Cma,) 
• time to Cm~x (tm~x) 
• terminal plasma half-life (tl/2) calculated from the 
terminal log linear portion of the plasma 
concentration-time curve. 
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Regulatory authorities have not defined an acceptance 
range for pharmacokinetic comparability of inhaled frr- 
mulations. In this study we used the approach adopted for 
oral formulation where it is common practice to compare 
90% confidence intervals for treatment ratios. 
Urine samples were analysed for urinary-free cortisol for 
a 24-h period before and after drug administration. Cortisol 
concentrations were determined using liquid extraction 
followed by radioimmunoassay. The method required 
1.0 ml of urine "and was validated over the range 5- 
250/ag 1 - l .  
PHARMACOKINETIC ANALYSIS 
For AUC0-~, AL]Clast, Cmax and tl/2, geometric means, 
together with the corresponding 95% confidence intervals 
(CIs), were calculated using unpooled estimates of error. 
These parameters were log-transformed prior to all the 
analyses. AUCo-~, AUClast, and Cma x obtained after 
administration of fluticasone propionate via the HFA 
13,4a pMDI were tested for dose proportionality (17). Data 
were fitted to the following power model equation: 
Log (parameter) = a + [slope x log(dose)] 
A mean slope was estimated together with the associated 
90% CIs. 
AUCo-oo, AUCI,st, Cm~x and h/2 data for the 125 and 
250 #g HFA 134a pMDIs and for the corresponding CFC 
pMDIs were compared using analysis of variance (ANO- 
VA), allowing for effects due to subjects, periods and 
treatments. Estimates of the ratios of these parameters for 
the HFA 134a and corresponding CFC pMDI were 
calculated (125 and 250 FLg strengths), together with the 
associated 90% CIs. 
tm~x values for the HFA 134a and CFC pMDIs were 
compared using Wilcoxon's signed rank test (18). The 
estimates of the median differences between treatments 
were calculated together with 90% CIs. 
PHARMACODYNAMIC ANALYSIS 
Measurements of urinary cortisol excretion were summar- 
ized over the 24 h pre- and post-treatment by multiplying 
the cortisol concentration recorded by the volume of urine 
collected for the sampling time. Non-quantifiable cortisol 
concentrations were replaced by the half detection limit 
(0.25/~g l - l=  1/2 x0.5 pg 1-1) to calculate 24 h cortisol 
excretion. 
The 24-h urinary cortisol excretion data were log 
transformed and analysed using analysis of covariance 
(ANCOVA) allowing for effects due to subjects, periods, 
and treatment, with the pre-treatment responses as 
covariates. Estimates of geometric mean values were 
calculated for each treatment. Estimates of the cortisol 
excretion ratio were calculated for the HFA 134a and 
corresponding CFC pMDI (125 and 250 #g strengths) and 
for the 50 and 250 pg HFA 134a and the 125/ag HFA 134a 
pMDI, together with 95% CIs. 
Results 
Twenty-three healthy subjects (11 males and 12 females; 
median weight 65 kg) aged 19-49 years (median 25 years) 
entered the study. Twenty subjects completed all five 
treatment periods. 
PHARMACOKINETICS 
Mean fluticasone propionate plasma concentration time 
profiles for each treatment are presented in Fig. 1. 
Summary statistics for the pharmacokinetic parameters 
are listed in Table 1. Plasma fluticasone propionate 
concentrations increased quickly after dosing. Cm~x was 
achieved within 1 h in most subjects regardless of treatment 
and median tm~x was 0-67 h. 
AUCo_~ increased linearly with increasing dose of 
fluticasone propionate administered via the three HFA 
134a pMDIs (Fig. 2). The 90% CIs for the slope included 
unity for both Cm,x (slope=0"90; 90% CI: 0.78-1.01) and 
AUCo-~ (slope=l'01; 90% CI: 0.88-1.14) following 
power model analysis. This confirmed ose proportionality 
of systemic exposure for the fluticasone propionate HFA 
134a inhalers. 
Comparative pharmacokinetic data for the HFA 134a 
and CFC pMDIs are presented in Table 2 and Fig. 3. 
Higher fluticasone propionate plasma concentrations were 
observed after inhalation via the fluticasone propionate 125 
/zg CFC inhaler than after using the fluticasone propionate 
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F~c. 1. Mean fluticasone propionate (FP) plasma 
concentrations after inhalation of single doses of FP 400, 
1000 and 2000/~g, respectively, via a 50, 125, and 250/~g 
hydrofluoroalkane (HFA) 134a pressurized metered ose 
inhaler (pMDI) and single doses of FP 1000 and 2000/~g, 
respectively, via a 125 and 250 #g chlorofluorocarbon 
(CFC) pMDI (@ 50/tg HFA 134a pMDI; • 125 #g HFA 
134a pMDI; • 250/Lg HFA 134a pMDI; • 125/~g CFC 
pMDI; • 250 sg CFC pMDI). 
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TABLE I. Pharmacokinetic parameters for fluticasone propionate (FP) hydrofluoroalkane (HFA) 134a pressurized metered 
dose inhalers (pMDI) 
FP 50 ltg HFA pMDI 
(dose: 400 #g) 
FP 125 #g HFA pMDI 
(dose: 1000/ag) 
FP 250/ag HFA pMDI 
(dose: 2000 #g) 
AUCo_~ (ng I-  i .  h) 
Geometric mean 693" I 1547.1 3365-4 
95% CI (556.0, 863.9) (I 165.6, 2053.5) (2767.8, 4092-0) 
Cma.~ (ng 1-I) 
Geometric mean I 18-7 237.7 506.8 
95% CI (103-9, 135.5) (190.9, 295.9) (438-3, 585-9) 
tmax (h) 
Median 0.67 0.67 0.67 
Range (0" 167, 2.00) (0.167, 3.00) (0-167, 3.00) 
tl/2 (h) 
Geometric mean 4.07 5"21 6" 31 
95% CI (3"30, 5"02) (4.14, 6"57) (5.57, 7.15) 
AUCo_~o, area under the plasma-concentration time curve extrapolated to infinity; CI, confidence interval; Cmax, maximum 
plasma concentration; tmax, time to Cmax, tl/2, terminal plasma half-life. 
125 pg HFA 134a inhaler. AUCo-~o and Cmax for the HFA 
134a inhaler were approximately 33% lower compared to 
values for the CFC inhaler. However, fluticasone propio- 
nate plasma concentrations for the 250/ag HFA 134a and 
CFC pMDIs were similar. 
ti/2 was 5.21 and 6.31 h respectively, for fluticasone 
propionate 1000 and 2000/~g, and was unaffected by the 
propellant used. A lower estimate of h/2 (4.07 h) after 
administration of fluticasone propionate 400/~g was due to 
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FtG. 2. Relationship between mean systemic exposure and 
nominal dose for fluticasone propionate (FP) 
hydrofluoroalkane (HFA) 134a pressurized metered ose 
inhalers (pMDI) after inhalation of single doses of FP 
400, 1000 and 2000 #g, respectively, via a 50, 125, and 
250/~g pMDI, respectively. (Geometric mean + 95% CI.) 
low plasma fluticasone propionate concentrations at later 
time points during the plasma concentration-time profile. 
The linear increase in AUCo-oo with increasing FPM 
dose for the three HFA 134a and two CFC pMDIs is 
shown in Fig. 3. The regression line for the plot shows that 
differences in FPM dose account for some of the differences 
in systemic exposure between the HFA 134a and CFC 
inhalers. Although the 95% CIs for the regression line 
included all the data points it is clear that variability in the 
FPM dose does not fully explain the variability in systemic 
exposure. 
PHARMACODYNAMICS 
Baseline cortisol concentrations were similar before each of 
the 24-h treatment periods (range 41.15--48.55/~g). There 
was a dose-related decrease from baseline in post-treatment 
excretion of cortisol which was unaffected by the propellant 
used (Table 2, Fig. 4). 
Discuss ion  
The FPM dose estimates the proportion of the dose with a 
particular size within the respirable range (<5 /~m). As 
would be expected for a drug with negligible oral 
bioavailability, there was a proportional relationship 
between fluticasone propionate systemic exposure and both 
FPM and nominal dose. 
The increase in fluticasone propionate plasma concentra- 
tion with dose occurred in a predictable, dose proportional 
fashion for the three strengths of the HFA 134a pMDIs and 
125 pg strength 
ratio HFA pMDI/CFC 
pMDI* 
AUCo_oo 
Geometric mean 0"67 0.88 
90% CI (0.57, 0.79) (0.75, 1"05) 
Cmax 
Geometric mean 0"63 1.0 I 
90%CI (0.54, 0.74) (0-86, 1.18) 
tmax 
Median 0" 17 0.25 
Range (-0.08, 0.42) ( -0.08,  0.50) 
t1/2 
Geometric mean 0-85 0.9 I 
90% CI (0-71, 1.01) (0.76, 1.09) 
Cortisol excretion 
Geometric mean 1.04 1.01 
95%CI (0.82, 1.32) (0.79, 1.29) 
250 pg strength 
ratio HFA pMDI/CFC 
pMDI* 
* Mean ratio for AUCo-oo. cm~, tl/2 and cortisol excretion and median difference for tmax" 
AUCo-oo, area under the plasma-concentration time curve extrapolated to infinity; CI, confidence interval; Cmax, maximum 
plasma concentration; tmax, time to Cmax; tl/2, terminal plasma half-life. 
resulted in dose-related reductions in urinary cortisol 
excretion. Thus, significant changes in fluticasone propio- 
nate systemic exposure could produce measurable changes 
in cortisol excretion. 
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TABLE 2. Comparison of pharmacokinetic and pharmacodynamic parameters for the fluticasone propionate 125 and 250 lag 
hydrofluoroalkane (HFA) 134a and chlorofluorocarbon (CFC) pressurized metered ose inhalers (pMDI) 
FIG 3. Relationship between mean systemic exposure and 
fine particle mass dose for fluticasone propionate (FP) 
after inhalation of single doses of FP 400, 1000 and 
2000 pg, respectively, via a 50, 125 and 250/~g 
hydrofluoroalkane (HFA) 134a pressurized metered ose 
inhaler (pMDI) (@) and single doses of FP 1000 and 
2000/tg, respectively, via a 125 and 250 #g 
chlorofluorocarbon (CFC) pMDI. (A) The regression line 
and 95% confidence intervals are shown. 
Differences between the HFA 134a and CFC pMDIs 
were examined by comparing fluticasone propionate 
systemic exposure and urinary cortisol excretion. The 250 
~g strength HFA 134a inhaler produced very similar 
systemic exposure (AUCo-~o and Cmax) to the CFC 
product; the 90% CIs included unity and there was no 
statistically significant difference between the two inhalers. 
For the 125 pg strength HFA 134a pMDI, the systemic 
exposure was 33% and 37% lower (AUCo_oo and Cmax, 
respectively) than for the CFC pMDI. However, the dose 
proportionality data for the three HFA 134a inhalers 
indicated that the systemic exposure from the 
125 pg HFA 134a inhaler was consistent with the other 
strengths. Therefore, this suggests that the 125 #g CFC 
pMDI produced a slightly higher exposure, rather than the 
HFA 134a pMDI producing a lower exposure. 
In this context it is important o note that the inhaler 
batches used in this study were typical production batches, 
in terms of emitted FPM dose. Based on typical inter-batch 
variability in FPM dose, a 1000 pg nominal dose, delivered 
from any of the inhalers tudied, would result in an emitted 
FPM dose of approximately 360--448/ag. This difference in 
FPM (88 #g) accounts for a potential change in the 
fiuticasone propionate plasma AUC of 352 ng l - I  h as 
predicted by the regression line .shown in Fig. 3. Therefore, 
although this study showed a difference between the HFA 
134a and CFC pMDIs at the 125 pg strength, repeating this 
study with different batches would produce a different 
result. However, although a well powered pharmacokinetic 
study is able to detect hese small differences, it is clear from 
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Flo. 4. Relatipnshi p between urinary cortisol excretion and fluticasone propionate (FP) dose for CFC and HFA 134a 
pMDIs after, inhalation of single doses of FP 400, I000 and 2000 #g, respectively, via a 50, 125 and 250 #g 
hydrofluoroalkane (HFA) 134a pressurized metered ose inhaler,(pMDI) (O) and single doses of FP 1000 and 2000 #g, 
respectively, via a 125 and 250 #g chlorofluorocarbon (CFC) pMDI (V), the data points represent geometric means. 
the cortisol data (Table 2) and from clinical data for the 
fluticasone propionate HFA 134a pMDI (19-21) that this 
degree of variability is not clinically relevant. 
The fluticasone propionate doses used in this study were 
generally higher than the fluticasone propionate doses used 
to treat patients with asthma, but were necessary to 
adequately assess dose proportionality using pharmacoki- 
netic data. It has also been shown that systemic exposure to 
fluticasone propionate is two to three-fold lower in asthma 
patients than in healthy subjects (16). Furthermore, the 
reductions in urinary .cortisol excretion observed in this 
study are unlikely to be seen clinically (22,23). 
In conclusion, the three strengths of the fluticasone 
propionate HFA 134a pMDI (50, 125 and 250 /ag) 
produced a dose proportional increase in systemic exposure 
to fluticasone propionate, and by inference lung deposition. 
In comparison to the fluticasone propionate CFC pMDI 
(125 and 250 pg strengths), the fluticasone propionate HFA 
134a pMDI produced a similar or lower systemic exposure 
to fluticasone propionate. The HFA 134a pMDIs were safe 
and well tolerated in healthy volunteers and overall there 
was no evidence of an altered risk of fluticasone propionate 
induced systemic side-effects with the new inhaler. 
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